ArticlebioRxiv : the preprint server for biology2026
Disulphide and sequence-encoded conformational priors guide nanobody structure prediction.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanobody binding is largely governed by the HCDR3 loop, which adopts distinct placement regimes relative to the framework: compact, framework-contacting (kinked blueprint) and solvent-exposed (extended blueprint). Many nanobodies also contain additional cysteines that form non-canonical disulphide bonds, imposing covalent constraints on binding-loop conformations. Current structure predictors are typically trained and benchmarked with smooth coordinate-based objectives, so models may appear reasonable under root-mean-square deviation (RMSD), while adopting an incorrect HCDR3 blueprint or failing to recover the native disulphide connectivity, impacting paratope geometry and functional interpretation. Here, we show that the HCDR3 blueprint is predictable from sequence alone, allowing for explicit constraints during modelling. We implement these principles into NbForge, a lightweight nanobody folding model that incorporates blueprint- and disulphide-aware inductive biases and is trained with filtered self-distillation. NbForge improves recovery of HCDR3 blueprint and non-canonical disulphide formation over previous lightweight models and achieves coordinate accuracy at par to state-of-the-art, large, resource-intensive predictors, while running at sub-second inference speed. We show that using NbForge monomer models as templates further improves the success rate of predicting nanobody-antigen complexes. Together, these results motivate blueprint- and disulphide-aware benchmarks for nanobody modelling beyond RMSD, and show that appropriate inductive biases can close the performance gap to heavyweight predictors. We make the sequence classifier (NbFrame) and NbForge available for download and via a user-friendly web server.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.